These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29455689)

  • 1. INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.
    Dintsios CM; Schlenkrich S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):196-204. PubMed ID: 29455689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
    Bittner S; Meuth SG
    Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
    Peinemann F; Labeit A
    J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree.
    Dintsios CM; Worm F; Ruof J; Herpers M
    Health Econ Rev; 2019 Dec; 9(1):35. PubMed ID: 31848760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
    Broich K; Löbker W; Schulte A; Beinlich P; Müller T
    Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
    Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
    Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
    Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
    Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interplay between marketing authorization and early benefit assessment of drugs].
    Beinlich P; Müller-Berghaus J; Sudhop T; Vieths S; Broich K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):227-31. PubMed ID: 25566840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Ruof J; Flückiger O; Andre N
    Drugs R D; 2015 Sep; 15(3):221-6. PubMed ID: 26286202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE supports allowing technology assessment bodies to provide advice to drug industry.
    Longson C; Crabb N; Osipenko L
    BMJ; 2014 Aug; 349():g5035. PubMed ID: 25121499
    [No Abstract]   [Full Text] [Related]  

  • 19. European Medicines Agency is attacked over proposal to allow technology assessment bodies to sell advice to drug industry.
    Wise J
    BMJ; 2014 Jul; 349():g4674. PubMed ID: 25033980
    [No Abstract]   [Full Text] [Related]  

  • 20. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.